Genomics England appoints Dr Rich Scott as Chief Executive Officer
Today (Wednesday 13 March) Genomics England announce the appointment of Dr Rich Scott as Chief Executive Officer (CEO). He will begin his role as CEO on 18 March 2024.
Rich is currently interim CEO of Genomics England, leading our work with participants and partners across the NHS, academia and industry in support of our mission to create a world where everyone can benefit from genomic healthcare.
The Board and I are delighted to welcome Rich as permanent CEO of Genomics England. From his arrival at Genomics England in 2015 to now, Rich has always shown his passion and commitment towards harnessing the power of genomics to deliver better care for patients and participants. Under Rich’s leadership, I know Genomics England will continue to build on the progress made over the last decade and move closer to the vision of a world where everyone can benefit from genomic healthcare. I look forward to working with Rich in this new role.
Baroness Nicola Blackwood
Chair of Genomics England
Rich first joined the organisation in 2015 and became Chief Medical Officer in 2021. During this time, he has overseen Genomics England’s support of the NHS’ world-first Whole Genome Sequencing (WGS) diagnostics service at national level. He’s also led the design of the Generation Study, a groundbreaking research study led by Genomics England in partnership with the NHS which aims to sequence the genomes of 100,000 newborn babies to understand whether we can improve our ability to diagnose and treat rare genetic conditions.
Rich is also a Consultant and Honorary Associate Professor in Clinical Genetics at Great Ormond Street Hospital for Children and the UCL Great Ormond Street Institute of Child Health where his practice focuses on diagnosing children with rare multisystem disorders.
I am absolutely delighted to have been appointed as the Chief Executive Officer of Genomics England.
Years of continued investment and scientific advances have placed the UK at the forefront of genomics. Over the next decade, genomics will become even more important across healthcare and research. I’m honoured to be leading Genomics England at this exciting time as we look to work with our partners and participants to build on our work to connect research and clinical care at national scale, enabling immediate healthcare benefits as well as advances for the future.
Dr Rich Scott
Dr Rich Scott's appointment as permanent CEO is excellent news for the research participants supported by Genomics England, and for patients with cancer and rare conditions. He has championed our interests since he first arrived at the company and I'm thrilled that we can continue this very strong working relationship. With my colleagues on the Participant Panel, I'd like to congratulate him and look forward to delivering even more for our community in the future.
Jillian Hastings Ward
Chair of the Participant Panel at Genomics England
